Canaccord Genuity Calls DexCom (DXCM) Quarter Solid, Says Momentum Building
Canaccord Genuity maintained a Buy rating on DexCom (NASDAQ: DXCM) with an adjusted price target of $19.00 (from $20).
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)